News of Note—Moderna’s combo vaccine, Seqirus revenue and more

newspaper
(Pixabay)

Here is some other vaccine news of note for the week:

> Moderna’s mRNA-1653, a combo vaccine designed to protect against human metapneumovirus and parainfluenza type 3, boosted serum neutralization titers against the two viruses, according to the company’s interim phase 1 data report. Release

> Seqirus’ revenue for the six months ended Dec. 31 grew 21% at constant currency to reach $949 million, driven largely by its flu vaccines, parent company CSL said in a half-year report. Report

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

> Vaxart plans to start phase 1 bivalent and phase 2 monovalent challenge studies for its oral norovirus vaccine in the first half of 2019, CEO Wouter Latour, M.D., said as the company reported fourth-quarter financial results. Release

> Health experts are calling on Facebook to stem the rise of anti-vaccination groups in which members post misinformation in a closed circle. The Guardian article

Suggested Articles

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.

Merck just last month won the world's first licensure for an Ebola vaccine. Now, an international group authorized funding to establish a stockpile.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.